Adjunctive Daptomycin Does Not Shorten the Duration of MSSA Bacteremia Compared to Standard-of-Care Therapy

A randomized, double-blind, placebo-controlled clinical trial of adults aged 18 years and older found that adjunctive daptomycin did not shorten the duration of methicillin-susceptible Staphylococcus aureus bacteremia compared to monotherapy with an antistaphylococcal beta-lactam antibiotic.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news